# Characterizing ceftriaxone tolerance in Neisseria gonorrhoeae across in vitro and in vivo models

**Authors:** Izumo Kanesaka, Anurag Kumar Bari, Saïd Abdellati, Thibaut Vanbaelen, Irith De Baetselier, Tessa de Block, Reinout Naesens, Basil Britto Xavier, John Rossen, Chris Kenyon, Sheeba Santhini Manoharan-Basil

PMC · DOI: 10.1128/msystems.01298-25 · mSystems · 2026-01-08

## TL;DR

This study shows how a strain of gonorrhea bacteria can survive ceftriaxone treatment despite appearing susceptible, potentially leading to treatment failure.

## Contribution

The first detailed characterization of ceftriaxone tolerance in Neisseria gonorrhoeae and its genetic and transcriptional basis.

## Key findings

- Ceftriaxone-tolerant N. gonorrhoeae strains survive drug exposure longer than non-tolerant strains in vitro and in vivo.
- Tolerant strains have non-synonymous mutations in pilE_3 and show altered gene expression in pilin and ribosomal genes.
- Tolerance may explain treatment failure despite standard susceptibility testing.

## Abstract

This study aims to characterize the phenotypic behavior and in vivo persistence of a ceftriaxone-tolerant Neisseria gonorrhoeae clinical isolate from a single patient and evaluate the potential role of tolerance in treatment failure. A previously identified ceftriaxone-tolerant vaginal isolate was compared with isogenic and clinical non-tolerant strains. Bacterial growth was assessed in vitro, and tolerance was quantified using the minimum duration required to kill 99% of the population (MDK99), and persistence was evaluated in an in vivo Galleria mellonella infection model. Whole-genome sequencing (WGS) and transcriptomic (RNA-sequencing [RNA-seq]) profiling were performed to identify tolerance-associated genetic and transcriptional signatures. The tolerant strain exhibited prolonged MDK99 values across ceftriaxone concentrations, persisting for up to 24 hours under drug exposure. It also showed delayed early-phase growth, suggesting a fitness cost. In vivo, the tolerant strain remained viable up to 8 hours after treatment, whereas non-tolerant strains were cleared. WGS revealed identical gene content across all isolates, but non-synonymous mutations in pilE_3, a type IV pilin gene, were exclusively present in tolerant strains. RNA-seq analysis showed upregulation of pilin-associated genes and downregulation of zinc-independent ribosomal paralogs (rpmE2 and ykgO), suggesting a combined mechanism of surface remodeling and translational suppression associated with the tolerant phenotype. Ceftriaxone tolerance enables prolonged survival of N. gonorrhoeae despite apparent susceptibility by standard MIC-based testing. This phenotype may contribute to treatment failure, recurrent infection, and ongoing transmission, indicating the need for revised diagnostic and therapeutic strategies.

Ceftriaxone remains the last reliable option for gonorrhea therapy, yet recurrent infections can occur despite isolates being classified as susceptible by MIC testing. One possible explanation is antibiotic tolerance, a phenotype that allows survival during drug exposure without changes in MIC. Although tolerance has been described in other pathogens, its role in gonococcal infection has remained poorly defined. In this study, we provide the first detailed characterization of a ceftriaxone-tolerant Neisseria gonorrhoeae clinical isolate associated with repeated treatment failure. By combining in vitro killing assays, an in vivo Galleria mellonella infection model, whole-genome sequencing, and transcriptomic profiling, we demonstrate that tolerance enables prolonged survival under ceftriaxone and is linked to pilin gene variation and ribosomal remodeling. These findings illustrate how a clinically observed phenomenon can be mechanistically dissected and emphasize tolerance as a hidden factor contributing to gonococcal persistence and potential treatment failure.

## Linked entities

- **Genes:** rpmE2 (50S ribosomal protein L31) [NCBI Gene 987268], ykgO (type B 50S ribosomal protein L36) [NCBI Gene 928792]
- **Chemicals:** ceftriaxone (PubChem CID 5479530)
- **Diseases:** gonorrhea (MONDO:0004277)
- **Species:** Neisseria gonorrhoeae (taxon 485), Galleria mellonella (taxon 7137)

## Full-text entities

- **Diseases:** infection (MESH:D007239), gonococcal infection (MESH:D006069)
- **Chemicals:** Ceftriaxone (MESH:D002443)
- **Species:** Neisseria gonorrhoeae (species) [taxon 485], Galleria mellonella (greater wax moth, species) [taxon 7137], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911389/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12911389/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12911389/full.md

---
Source: https://tomesphere.com/paper/PMC12911389